Skip to content
Action Kidney Cancer Logo Action Kidney Cancer Logo
  • Home
  • About us
  • Contact us
  • Help & support
  • Kidney cancer
  • Research
  • Get involved
  • Downloads
  • Home
  • About us
  • Contact us
  • Help & support
  • Kidney cancer
  • Research
  • Get involved
  • Downloads
Helpline
0800 121 8721
Email us
Fundraising Donate

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

  1. Home
  2. Uncategorized
  3. Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

Surgery after targeted therapy or immunotherapy for metastatic kidney cancer

5 Oct 2020

Tags
checkpoint inhibitors cytoreductive nephrectomy immunotherapy neoadjuvant therapy nephrectomy renal cell carcinoma targeted therapy
  • View Larger Image
Listen to this News
Print this News

Share this Page:

FacebookXLinkedInWhatsAppTumblrPinterestVkXingEmail

A recent retrospective study (looking back at the patients’ cases after treatment had occurred) has shown that patients with metastatic renal cell carcinoma (RCC) who were treated with targeted therapy, such as sunitinib or pazopanib, or immunotherapy, such as nivolumab, had better survival outcomes if went on to have surgery to remove the kidney. This is called neoadjuvant treatment.

There were 4,639 patients with metastatic RCC in the trial and who were treated with either immune checkpoint inhibitor or targeted therapy. A total of 4,202 patients were on a targeted therapy. Of these patients, 2,631 had nephrectomy while 1,571 did not. Meanwhile, 437 of the patients were on immune checkpoint inhibitors, 245 of whom had nephrectomy while 192 did not. The data came from more than 40 centres across the world.

The patients were followed for an average of 38.5 months. Patients who were treated with targeted therapy before they had their nephrectomy experienced an average overall survival of 26.5 months versus 10.3 months in those who did not have nephrectomy.

Patients who had immune checkpoint inhibitor treatment before nephrectomy had an average overall survival of 53.6 months versus 21.4 months for patients who were not on neoadjuvant immunotherapy.

However, not every patient with metastatic RCC will benefit from nephrectomy followed by targeted treatment or immunotherapy. Some studies, such a the CARMENA trial found that patients who had one risk factor (such as low haemoglobin or high calcium levels) benefited from surgery before receiving sunitinib, especially if they had only one site of disease spread.

Read more in Cure here

Listen to this News
Print this News

Share this Page:

FacebookXLinkedInWhatsAppTumblrPinterestVkXingEmail

Kidney cancer news

20 Jun 2025

Combination therapy shows promise for hereditary papillary kidney cancer

Read More

19 Jun 2025

Unprecedented boost for clinical trials under 10 Year Health Plan

Read More

13 Jun 2025

Kidney cancer research highlights from ASCO 2025

Read More

21 May 2025

The financial implications of a cancer diagnosis

Read More

19 May 2025

Cancer waiting times: latest updates

Read More

14 May 2025

Kidney cancer becoming more common in younger people?

Read More

30 Apr 2025

UK regulators approve injectable form of nivolumab for solid tumours

Read More

28 Apr 2025

Immunotherapy for the treatment of non-clear cell kidney cancer

Read More

7 Apr 2025

IKCC Global Kidney Cancer Summit

Read More

2 Apr 2025

Europe has approved subcutaneous nivolumab for solid tumours

Read More

28 Mar 2025

The Big Cancer52 Conversation

Read More

24 Mar 2025

A urine test to detect the return of kidney cancer

Read More

Most used tags

renal cell carcinoma immunotherapy combination therapy checkpoint inhibitors Cancer nivolumab TKIs overall survival Opdivo sunitinib cabozantinib Sutent kidney cancer progression-free survival NHS England biomarkers ipilimumab pembrolizumab Cabometyx COVID-19 axitinib cancer survival non-clear cell kidney cancer VEGF inhibitors Inlyta coronavirus Yervoy risk factors adjuvant therapy Keytruda metastases targeted therapy papillary RCC everolimus biological markers ASCO Afinitor cancer outcomes first-line treatment NICE

Archives

  • 2025: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2024: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2023: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2022: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2021: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2020: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2019: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2018: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2017: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • 2016: Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec
  • About kidney cancer
  • Kidney cancer news
  • Kidney cancer treatments
  • Newsletter
  • Glossary
  • Useful links

Address

Action Kidney Cancer

11th Floor
3 Piccadilly Place
Manchester M1 3BN

Helpline

0800 121 8721
Email Us

About Action Kidney Cancer

We are the UK’s largest and most active patient-led kidney cancer charity. Whether you are a patient, survivor or someone you know has been diagnosed with kidney cancer, you have come to the right place to find support and information, and to be part of a caring and knowledgeable community of people: We are here to help you.
Registered charity in England, Wales (1164238), and Scotland (SC051330).
© Copyright Action Kidney Cancer 2021

Links

Home

About us

Donate

Contact us

Our partners

Branding by Kingswood Marketing

Policies

Website Policies

Complaints Policy

Equal Opportunities Policy

Information Governance Policy

Social Media Policy

Health Information Policy

Follow

X-Twitter
Our Website Design Specialist | Douglass Digital

Helpline: 0800 121 8721

support@actionkidneycancer.org

Go to Top